Pharvaris

Historical price data

Pharvaris is a late-stage biopharma focused on transforming the treatment paradigm for bradykinin-mediated angioedema, particularly hereditary angioedema (HAE), through oral therapies. Its lead asset, deucrictibant, is a novel oral B2 receptor antagonist in pivotal Phase 3 trials for both on-demand and prophylactic treatment of HAE attacks. The company's strategy is to provide patients and physicians with effective, convenient, and well-tolerated oral alternatives to the current standard of injectable therapies, potentially capturing a significant share of the growing HAE market.

Rational drug design of oral small-molecule antagonists targeting the bradykinin B2 receptor, with optimized immediate-release and extended-release formulations for on-demand and prophylactic treatment.

Competition includes Takeda (injectable C1-inhibitors, oral berotralstat), CSL Behring (C1-inhibitors), and KalVista (oral sebetralstat). Pharvaris differentiates by targeting the B2 receptor with a single molecule for both prophylaxis and on-demand use, aiming for best-in-class oral efficacy and tolerability.